Inclusion Criteria:  Age > 18 years Written informed consent Diagnosis of symptomatic severe aortic stenosis, or clinically relevant degeneration of previously implanted surgical aortic valve bioprosthesis Patient undergoing TAVI according to local institutional protocol and following Heart Team discussion. High-quality ECG gated computed tomography (CT) scan of the heart and aorta Presence of 2 or more of the following risk factors for CAO (high-risk):  6a. TAVI in native valves: height of the coronary ostium (<9 mm), sinuses of Valsalva width <30 mm, leaflet tips extending above the coronary ostia or the sino-tubular junction.  6b. VIV-TAVI (patients undergoing BASILICA as first prevention strategy are also included): surgical bioprosthesis type: with supra-annular position, high leaflet profile, externally mounted leaflets stented valve, stentless valves, and bulky leaflets, low-lying coronary ostia (< 9 mm from the ostia to the sewing ring), narrow sinuses of Valsalva (<30 mm by width for Valsalva sinuses), virtual THV-coronary (VTC) distance <4 mm, virtual THV-STJ (VT-STJ) distance < 2.5-3.5 mm: to be considered in cases where VTC >4mm but the leaflet extends above or very close (up to 2mm below) to the STJ plane.  Exclusion Criteria:  Age < 18 years Pregnancy Absence of informed consent Angiographic or functional critical stenosis of the at-risk coronary artery (%DS > 70 for right coronary artery, > 50 for left main, or positive functional assessment), requiring revascularization regardless the risk of CAO. Signs or symptoms of acute (unstable) myocardial ischemia Reduced survival expectancy due to severe co-morbidities (<1 year)